Chronic Kidney Disease: Treatment and Monitoring Strategies
All adults with CKD and eGFR ≥20 ml/min per 1.73 m² should be treated with an SGLT2 inhibitor if they have urine ACR ≥200 mg/g or heart failure, and RAS inhibitors (ACEi or ARB) should be continued even when eGFR falls below 30 ml/min per 1.73 m² 1.
Core Pharmacotherapy Algorithm
First-Line Therapy: SGLT2 Inhibitors
Strong indications (1A recommendation):
- Type 2 diabetes with eGFR ≥20 ml/min per 1.73 m² 1
- eGFR ≥20 ml/min per 1.73 m² with urine ACR ≥200 mg/g (≥20 mg/mmol) 1
- Heart failure, regardless of albuminuria level 1
Moderate indication (2B recommendation):
- eGFR 20-45 ml/min per 1.73 m² with urine ACR <200 mg/g 1
Critical management points:
- Continue SGLT2i even if eGFR drops below 20 ml/min per 1.73 m² unless not tolerated or kidney replacement therapy initiated 1
- The reversible eGFR decrease on initiation is not an indication to stop therapy 1
- Withhold during prolonged fasting, surgery, or critical illness due to ketosis risk 1
Second-Line: RAS Inhibition (ACEi or ARB)
Initiation criteria:
- Start for albuminuria reduction, hypertension control, or heart failure with reduced ejection fraction 1
- Can be initiated even with normal to mildly increased albuminuria (A1) for specific indications 1
Continuation rules:
- Continue unless serum creatinine rises >30% within 4 weeks of initiation or dose increase 1
- Continue even when eGFR falls below 30 ml/min per 1.73 m² 1
- Only reduce dose or discontinue for: symptomatic hypotension, uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms when eGFR <15 ml/min per 1.73 m² 1
Hyperkalemia management:
- Treat hyperkalemia with potassium binders rather than stopping RASi 1
Third-Line: Nonsteroidal Mineralocorticoid Receptor Antagonists
Indication (2A recommendation):
- Type 2 diabetes with eGFR >25 ml/min per 1.73 m² 1
- Normal serum potassium concentration 1
- Albuminuria >30 mg/g (>3 mg/mmol) despite maximum tolerated RASi dose 1
- Can be added to RASi + SGLT2i combination 1
Finerenone dosing algorithm based on potassium:
| K+ ≤4.8 mmol/L | K+ 4.9-5.5 mmol/L | K+ >5.5 mmol/L |
|---|---|---|
| Initiate: 10 mg daily if eGFR 25-59; 20 mg daily if eGFR ≥60 | Continue current dose; Monitor K+ every 4 months | Hold finerenone; Adjust diet/medications; Recheck K+; Reinitiate if K+ ≤5.0 |
- Monitor potassium at 1 month after initiation, then every 4 months 1
- Increase to 20 mg daily if tolerating 10 mg with normal potassium 1
Fourth-Line: GLP-1 Receptor Agonists
Indication (1B recommendation):
- Type 2 diabetes with CKD not achieving glycemic targets despite metformin and SGLT2i 1
- Prioritize agents with documented cardiovascular benefits 1
Blood Pressure Management
Target: <140/90 mm Hg minimum; systolic <120 mm Hg for those tolerant of therapy 2
- Use ACEi or ARB as first-line agents 2
Cardiovascular Risk Reduction
Statin therapy: Recommended for all CKD patients to reduce atherosclerotic cardiovascular disease risk 3
Monitoring Strategy
Laboratory Monitoring
- eGFR calculation: Use CKD-EPI creatinine equation without race variable 2
- Confirm eGFR: Measure serum cystatin C when possible, especially for drug dosing decisions 3, 2
- Albuminuria: Monitor urine albumin-to-creatinine ratio regularly 1
Metabolic Acidosis
- Consider treatment when serum bicarbonate <18 mmol/L in adults 1
- Monitor to ensure bicarbonate doesn't exceed upper limit of normal and doesn't adversely affect BP, potassium, or fluid status 1
Critical Pitfalls to Avoid
- Don't stop SGLT2i for initial eGFR dip - this is expected and reversible 1
- Don't discontinue RASi for creatinine rise <30% within 4 weeks 1
- Don't use hyperkalemia as automatic reason to stop RASi - treat the hyperkalemia instead 1
- Don't stop ACEi/ARB when eGFR drops below 30 - continue unless specific contraindications 1
- Avoid iodinated contrast in advanced CKD - temporarily reduces eGFR 2
Nephrology Referral Indications
- High risk of progression to end-stage renal disease based on Kidney Failure Risk Equation 4
- eGFR <30 ml/min per 1.73 m² 2
- Rapidly declining kidney function
- Consideration for kidney replacement therapy or conservative management 5
Special Populations
Pregnancy and gender-specific considerations require individualized approaches beyond standard guidelines 6. SGLT2 inhibitors may interact with anemia management in CKD, requiring coordinated monitoring 6.
The 2024 KDIGO guidelines represent a paradigm shift toward aggressive, multi-drug therapy for CKD, with SGLT2 inhibitors now central to management regardless of diabetes status - a major departure from previous RASi-centric approaches 1.